Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Filing of QuantumRD patents in nine countries

7 Jan 2013 07:00

RNS Number : 8905U
ViaLogy PLC
07 January 2013
 



VIALOGY PLC

FILES QUANTUMRD PATENTS IN NINE COUNTRIES

 

London, UK January 7, 2013. ViaLogy PLC(LSE/AIM: VIY) announces completion of certain patent filings in nine key energy markets and preliminary filings in the European region for QuantumRD, its core seismic data interpretation technology for reservoir discovery and hydrocarbon resource estimation. These additional filings further strengthen ViaLogy's intellectual property in anticipation of expanded usage in countries such as India where ViaLogy is already working with ONGC, or to support opportunities for adoption of QuantumRD in new territories.

ViaLogy believes that the technology has reached a level of maturity, capability and scalability that warrant extended patent protection. Enforceable coverage in specific national markets is essential because the laws of the country where the technology is used have legal precedence over the technology's country of origin. The filings cover QuantumRD use in conventional sandstone reservoirs, carbonates and nonconventional shale oil/gas plays for both onshore and offshore use. They are timely, inasmuch as ViaLogy is already working with large clients who have a global footprint. The nine countries are Brazil, China, Russia, India, Canada, Mexico, Qatar, Bahrain and Israel; the regional filings are those 38 countries covered by the European Patent Convention. ViaLogy now maintains the option of filing in each of those countries.

ViaLogy has already received from the US Department of Commerce an EAR99 export approval classification for oil and gas exploration and field development using QuantumRD® to offer services and licensing in all the above designated countries.

ViaLogy CEO Robert Dean said, "Our business strategy is to secure patents globally for QuantumRD, reflecting what we believe will be its widespread future use and the fact that the exploration and production industry is global in nature. Our EAR99 approval, global patent allowances and filings for QuantumRD, and for the underlying core technology Quantum Resonance Interferometry, are attractive for clients as they prioritize which country-specific oil and gas fields to develop with this technology. We felt some urgency to file because of our efforts with prospective clients, and we don't want to risk the technology being used in markets where it's not protected."

For further information contact: 

ViaLogy PLC

Terry Bond, Chairman - UK & Europe +44 (0) 1235-834734

Nominated Advisor and Broker to ViaLogy PLC (Seymour Pierce)

Mark Percy/Catherine Leftley, Corporate Finance +44 (0) 20-7107-8000

Katie Ratner/David Banks, Corporate Broking +44 (0) 20-7107-8000

 

About ViaLogy:

ViaLogy provides reservoir characterization, geophysical imaging and hydrocarbon sizing services to global oil and gas customers based on proprietary, patented active signal processing technology. ViaLogy's QuantumRD platform assists clients in de-risking prospects over a broad range of subsurface lithologies and complex stratigraphies to generate drilling targets, position offsets and enhance recovery. ViaLogy's core technology rapidly and accurately detects weak signals buried in high noise background and clutter, and is applicable to active/passive seismic, electromagnetic and magneto telluric data. By exploiting normally disregarded noise variations induced by changes in porosity, fluid presence and permeability across the formation, and adding computer-designed noise to the data, ViaLogy is able to amplify subtle noise variations to enhance areal and depth resolution in complex lithologies that are not achievable through conventional means. For more information on ViaLogy, visit www.vialogy.com.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRABUGDBLXGBGXS
Date   Source Headline
7th Feb 20177:00 amRNSSouthern Europe Business Update
10th Jan 20173:33 pmRNSResult of General Meeting
10th Jan 20177:15 amRNSHardman Research: Yourgene improves growth
21st Dec 20164:00 pmRNSPosting of Circular
21st Dec 20167:00 amRNSHalf year results
21st Dec 20167:00 amRNSConditional Acquisition of Yourgene Bioscience
21st Nov 20167:00 amRNSPremaitha establishes first service lab in Asia
31st Oct 20167:00 amRNSPremaitha welcomes UK Govt. decision on NIPT
27th Oct 20164:10 pmRNSResult of AGM
27th Oct 20167:00 amRNSAGM Statement
21st Oct 20167:00 amRNSGrant of Options
3rd Oct 20167:15 amRNSHardman Research: Excellent first year for IONA®
30th Sep 20163:38 pmRNSNotice of AGM
30th Sep 20167:00 amRNSFinal Results
23rd Sep 201610:42 amRNSHolding(s) in Company
23rd Sep 20168:50 amRNSNotice of results & appointment of broker
23rd Sep 20168:50 amRNSInvestment agreement extension with Thermo Fisher
8th Sep 20169:08 amRNSDirectorate Change
6th Jul 20167:00 amRNSDirectorate Change
4th Jul 20167:00 amRNSProgress on anti-trust objections to litigation
22nd Jun 20167:00 amRNSAdoption of Financial Reporting Standard (FRS) 101
22nd Apr 201610:45 amRNSUpdate on competitor patent litigation
20th Apr 201611:14 amRNSHardman Research: IONA sales & litigation update
20th Apr 20167:00 amRNSPatent Litigation Rescheduled
18th Apr 20161:13 pmRNSHardman & Co Issues Research Report
18th Apr 20161:03 pmRNSHardman & Co Issues Research Report
14th Apr 20167:00 amRNSHolding(s) in Company
13th Apr 20169:52 amRNSHolding(s) in Company
13th Apr 20167:00 amRNSHoldings in Company, Director's Shareholding
11th Apr 20167:00 amRNSTrading Update
29th Mar 20167:00 amRNSPremaitha announces tenth customer laboratory
21st Mar 20167:00 amRNSDistribution Agreements in the Middle East
9th Mar 20165:21 pmRNSHolding in Company, Directors' Dealing Replacement
9th Mar 20163:33 pmRNSHolding in Company, Directors' Dealings
9th Mar 20167:00 amRNSDistribution Agreement with GeNext - Russia
7th Mar 20167:00 amRNSAppointment of Joint Broker
3rd Feb 20167:00 amRNSPremaitha partners with Visional Medical in India
2nd Feb 20167:00 amRNSPremaitha partners with Leeds Hospitals NHS Trust
28th Jan 20167:00 amRNSHardman & Co Research Report: IONA®-Up and running
27th Jan 20167:00 amRNSTwo new customers signed for clinical lab service
26th Jan 20162:29 pmRNSUpdate on UK Litigation Timing
15th Jan 20167:00 amRNSPremaitha welcomes NSC recommendation on NIPT
8th Jan 201612:40 pmRNSUpdate on competitor patent litigation
18th Dec 20157:00 amRNSDirector/PDMR Shareholding
16th Dec 20155:53 pmRNSHolding(s) in Company
15th Dec 20157:00 amRNSHardman Issues Research Report
14th Dec 20157:00 amRNSInvestment Agreement with Thermo Fisher Scientific
14th Dec 20157:00 amRNSHalf Yearly Report
11th Dec 20157:00 amRNSNotice of Half Year Results
2nd Dec 20157:00 amRNSFirst IONA® testing service in France at LaboSud

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.